中华皮肤科杂志 ›› 2025, e0250045.doi: 10.35541/cjd.20250045
• 指南与共识 • 上一篇
中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会
收稿日期:2025-01-24
修回日期:2025-06-17
发布日期:2025-09-24
通讯作者:
耿松梅;王刚
E-mail:gengsongmei73@163.com; xjwgang@fmmu.edu.cn
Chinese Society of Dermatology; Chinese Dermatologist Association
Received:2025-01-24
Revised:2025-06-17
Published:2025-09-24
Contact:
Geng Songmei; Wang Gang
E-mail:gengsongmei73@163.com; xjwgang@fmmu.edu.cn
摘要： 【摘要】 坏疽性脓皮病（PG）是一种罕见的中性粒细胞性皮病，其最常见的临床表现是在正常或创伤部位皮肤出现潜行性发展的溃疡。本病常合并其他系统疾病。早期确诊及规范治疗对于PG及相关合并疾病的管理非常重要，我国目前尚无相关诊疗共识及指南。中华医学会皮肤性病学分会和中国医师协会皮肤科医师分会组织相关领域专家，综合国内外最新研究进展、国际共识，采用推荐意见分级的评估、制定与评价分级（GRADE），通过德尔菲法对PG诊断标准、严重程度评估以及治疗策略等方面达成共识，以指导我国PG的诊疗及对患者长病程管理。
中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. [开放获取] 坏疽性脓皮病诊疗中国专家共识（2025）[J]. 中华皮肤科杂志, 2025,e0250045. doi:10.35541/cjd.20250045
Chinese Society of Dermatology, Chinese Dermatologist Association. Expert consensus on diagnosis and treatment of pyoderma gangrenosum （2025 edition）[J]. Chinese Journal of Dermatology,2025,e0250045. doi:10.35541/cjd.20250045
| ［1］ | Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction⁃GRADE evidence profiles and summary of findings tables［J］. J Clin Epidemiol, 2011,64（4）:383⁃394. doi: 10.1016/j.jclinepi.2010.04.026. |
| ［2］ | Xu A, Balgobind A, Strunk A, et al. Prevalence estimates for pyoderma gangrenosum in the United States: an age⁃ and sex⁃adjusted population analysis［J］. J Am Acad Dermatol, 2020,83（2）:425⁃429. doi: 10.1016/j.jaad.2019.08.001. |
| ［3］ | Langan SM, Groves RW, Card TR, et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study［J］. J Invest Dermatol, 2012,132（9）:2166⁃2170. doi: 10.1038/jid.2012.130. |
| ［4］ | Kikuchi N, Hiraiwa T, Ohashi T, et al. Pyoderma gangrenosum possibly triggered by adalimumab［J］. Eur J Dermatol, 2012,22（6）:804⁃805. doi: 10.1684/ejd.2012.1849. |
| ［5］ | Pollack IR, Wolner ZJ, Hammett J, et al. Pyoderma gangrenosum in a patient on ixekizumab［J］. JAAD Case Rep, 2021,16:152⁃154. doi: 10.1016/j.jdcr.2021.08.021. |
| ［6］ | Rudolph BM, Staib F, Von Stebut E, et al. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma ⁃ simultaneous occurrence of pyoderma gangrenosum and colitis［J］. Eur J Dermatol, 2014,24（2）:268⁃269. doi: 10.1684/ejd.2014.2297. |
| ［7］ | Wu BC, Patel ED, Ortega⁃Loayza AG. Drug⁃induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum［J］. Br J Dermatol, 2017,177（1）:72⁃83. doi: 10.1111/bjd.15193. |
| ［8］ | Akahoshi⁃Ikeda M, Yoshizawa S, Motoshita J, et al. A case of pyoderma gangrenosum in a patient with rheumatoid arthritis treated with abatacept［J］. Acta Derm Venereol, 2016,96（6）:822⁃823. doi: 10.2340/00015555⁃2380. |
| ［9］ | Lim RK, Negbenebor NA, Lin EM, et al. Cocaine-induced pyoderma gangrenosum with negative anti-neutrophil cytoplasmic antibodies: a case report[J]. Int J Dermatol Venerol, 2023. doi：10.1097/JD9.0000000000000332. |
| ［10］ | Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab［J］. Arch Dermatol, 2011,147（10）:1203⁃1205. doi: 10.1001/archdermatol.2011.168. |
| ［11］ | Caproni M, Antiga E, Volpi W, et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum［J］. Br J Dermatol, 2015,173（1）:275⁃278. doi: 10.1111/bjd.13670. |
| ［12］ | Wang EA, Steel A, Luxardi G, et al. Classic ulcerative pyoderma gangrenosum is a T cell⁃mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies［J］. Front Immunol, 2017,8:1980. doi: 10.3389/fimmu.2017.01980. |
| ［13］ | Nesterovitch AB, Gyorfy Z, Hoffman MD, et al. Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 （PTPN6/SHP1） may contribute to neutrophilic dermatoses［J］. Am J Pathol, 2011,178（4）:1434⁃1441. doi: 10.1016/j.ajpath. 2010.12.035. |
| ［14］ | Nesterovitch AB, Hoffman MD, Simon M, et al. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum［J］. Clin Exp Dermatol, 2011,36（8）:889⁃895. doi: 10.1111/j.1365⁃2230.2011.04137.x. |
| ［15］ | Moura RR, Brandão L, Moltrasio C, et al. Different molecular pathways are disrupted in pyoderma gangrenosum patients and are associated with the severity of the disease［J］. Sci Rep, 2023,13（1）:4919. doi: 10.1038/s41598⁃023⁃31914⁃z. |
| ［16］ | Takeuchi F, Sterilein RD, Hall RP 3rd. Increased E⁃selectin, IL⁃8 and IL⁃10 gene expression in human skin after minimal trauma［J］. Exp Dermatol, 2003,12（6）:777⁃783. doi: 10.1111/j.0906⁃6705.2003.00088.x. |
| ［17］ | Maverakis E, van den Elzen P, Sercarz EE. Self⁃reactive T cells and degeneracy of T cell recognition: evolving concepts⁃from sequence homology to shape mimicry and TCR flexibility［J］. J Autoimmun, 2001,16（3）:201⁃209. doi: 10.1006/jaut.2000.0493. |
| ［18］ | Henry CM, Sullivan GP, Clancy DM, et al. Neutrophil⁃derived proteases escalate inflammation through activation of IL⁃36 family cytokines［J］. Cell Rep, 2016,14（4）:708⁃722. doi: 10. 1016/j.celrep.2015.12.072. |
| ［19］ | Foster AM, Baliwag J, Chen CS, et al. IL⁃36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin［J］. J Immunol, 2014,192（12）:6053⁃6061. doi: 10.4049/jimmunol. 1301481. |
| ［20］ | Rubas K, Reich A, Nowicka⁃Suszko D, et al. The role of interleukins 6, 8, 17 and 23 in the pathogenesis of pyoderma gangrenosum［J］. J Eur Acad Dermatol Venereol, 2023,37（5）:e660⁃e662. doi: 10.1111/jdv.18683. |
| ［21］ | Gaffen SL, Jain R, Garg AV, et al. The IL⁃23⁃IL⁃17 immune axis: from mechanisms to therapeutic testing［J］. Nat Rev Immunol, 2014,14（9）:585⁃600. doi: 10.1038/nri3707. |
| ［22］ | Li S, Ying S, Fang H, et al. Gasdermin D⁃dependent neutrophil extracellular traps exacerbate cytokine storm contributing to pyoderma gangrenosum pathogenesis［J］. iScience, 2025,28（3）:111925. doi: 10.1016/j.isci.2025.111925. |
| ［23］ | Yamamoto T, Yamasaki K, Yamanaka K, et al. Clinical guidance of pyoderma gangrenosum 2022［J］. J Dermatol, 2023,50（9）:e253⁃e275. doi: 10.1111/1346⁃8138.16845. |
| ［24］ | Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum［J］. Nat Rev Dis Primers, 2020,6（1）:81. doi: 10.1038/s41572⁃020⁃0213⁃x. |
| ［25］ | Tolkachjov SN, Fahy AS, Wetter DA, et al. Postoperative pyoderma gangrenosum （PG）: the Mayo Clinic experience of 20 years from 1994 through 2014［J］. J Am Acad Dermatol, 2015,73（4）:615⁃622. doi: 10.1016/j.jaad.2015.06.054. |
| ［26］ | Kechichian E, Haber R, Mourad N, et al. Pediatric pyoderma gangrenosum: a systematic review and update［J］. Int J Dermatol, 2017,56（5）:486⁃495. doi: 10.1111/ijd.13584. |
| ［27］ | Steele RB, Nugent WH, Braswell SF, et al. Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment［J］. Br J Dermatol, 2016,174（1）:77⁃87. doi: 10.1111/bjd.14230. |
| ［28］ | Kikuchi N, Hanami Y, Miura T, et al. Pyoderma gangrenosum following surgical procedures［J］. Int J Dermatol, 2010,49（3）:346⁃348. doi: 10.1111/j.1365⁃4632.2009.04201.x. |
| ［29］ | Lekwuttikarn R, Teng J. Cutaneous manifestations of nutritional deficiency［J］. Curr Opin Pediatr, 2018,30（4）:505⁃513. doi: 10. 1097/MOP.0000000000000652. |
| ［30］ | Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review［J］. J Cutan Pathol, 2003,30（2）:97⁃107. doi: 10.1034/j. 1600⁃0560.2003.00024.x. |
| ［31］ | Jorizzo JL, Solomon AR, Zanolli MD, et al. Neutrophilic vascular reactions［J］. J Am Acad Dermatol, 1988,19（6）:983⁃1005. doi: 10.1016/s0190⁃9622（88）70264⁃9. |
| ［32］ | Magro CM, Crowson AN. The cutaneous neutrophilic vascular injury syndromes: a review［J］. Semin Diagn Pathol, 2001,18（1）:47⁃58. |
| ［33］ | Quimby SR, Gibson LE, Winkelmann RK. Superficial granulomatous pyoderma: clinicopathologic spectrum［J］. Mayo Clin Proc, 1989,64（1）:37⁃43. doi: 10.1016/s0025⁃6196（12）65301⁃4. |
| ［34］ | Wilson⁃Jones E, Winkelmann RK. Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum［J］. J Am Acad Dermatol, 1988,18（3）:511⁃521. doi: 10.1016/s0190⁃9622（88）70074⁃2. |
| ［35］ | 胡清洁, 周敏, 姚煦. 坏疽性脓皮病36例临床特点分析及PARACELSUS评分与Delphi标准的比较［J］. 中华皮肤科杂志, 2023,56（5）:410⁃414. doi: 10.35541/cjd.20220825. |
| ［36］ | Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta⁃analysis［J］. Am J Clin Dermatol, 2018,19（4）:479⁃487. doi: 10.1007/s40257⁃018⁃0356⁃7. |
| ［37］ | 江燕云, 李骥, 李玥, 等. 溃疡性结肠炎并发坏疽性脓皮病八例研究［J］. 中华皮肤科杂志, 2017,50（9）:623⁃625. doi: 10. 3760/cma.j.issn.0412⁃4030.2017.09.001. |
| ［38］ | 许秋云, 纪超. 坏疽性脓皮病系统合并症的研究进展[J]. 2025, 58 (4): 369⁃373. doi: 10.35541/cjd.20240424. |
| ［39］ | Montagnon CM, Fracica EA, Patel AA, et al. Pyoderma gangrenosum in hematologic malignancies: A systematic review［J］. J Am Acad Dermatol, 2020,82（6）:1346⁃1359. doi: 10.1016/j.jaad.2019.09.032. |
| ［40］ | Marzano AV, Borghi A, Wallach D, et al. A comprehensive review of neutrophilic diseases［J］. Clin Rev Allergy Immunol, 2018,54（1）:114⁃130. doi: 10.1007/s12016⁃017⁃8621⁃8. |
| ［41］ | Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment［J］. Am J Clin Dermatol, 2017,18（4）:555⁃562. doi: 10.1007/s40257⁃017⁃0265⁃1. |
| ［42］ | Kastner DL, Aksentijevich I, Goldbach⁃Mansky R. Autoinflammatory disease reloaded: a clinical perspective［J］. Cell, 2010,140（6）:784⁃790. doi: 10.1016/j.cell.2010.03.002. |
| ［43］ | Satoh TK, Mellett M, Contassot E, et al. Are neutrophilic dermatoses autoinflammatory disorders?［J］. Br J Dermatol, 2018,178（3）:603⁃613. doi: 10.1111/bjd.15105. |
| ［44］ | Janowska A, Papa G, Romanelli M, et al. 5% Lidocaine hydrochloride cream for wound pain relief: a multicentre observational study［J］. J Invest Surg, 2022,35（1）:49⁃52. doi: 10.1080/08941939.2020.1821134. |
| ［45］ | Holman M. Using tap water compared with normal saline for cleansing wounds in adults: a literature review of the evidence［J］. J Wound Care, 2023,32（8）:507⁃512. doi: 10.12968/jowc. 2023.32.8.507. |
| ［46］ | Lee FG, Song E, Wallace SJ, et al. Non⁃surgical management of complex refractory pyoderma gangrenosum with negative pressure wound therapy with instillation［J］. Cureus, 2021,13（10）:e18951. doi: 10.7759/cureus.18951. |
| ［47］ | Hodson EL, Kranyak A, Salem I, et al. Adjunctive hyperbaric oxygen treatment for challenging pyoderma gangrenosum cases［J］. J Tissue Viability, 2024,33（3）:449⁃451. doi: 10.1016/j.jtv.2024.06.001. |
| ［48］ | Cohen PR. Neutrophilic dermatoses: a review of current treatment options［J］. Am J Clin Dermatol, 2009,10（5）:301⁃312. doi: 10.2165/11310730⁃000000000⁃00000. |
| ［49］ | Lyon CC, Smith AJ, Griffiths CE, et al. Peristomal dermatoses: a novel indication for topical steroid lotions［J］. J Am Acad Dermatol, 2000,43（4）:679⁃682. doi: 10.1067/mjd.2000.106237. |
| ［50］ | Wenzel J, Gerdsen R, Phillipp⁃Dormston W, et al. Topical treatment of pyoderma gangraenosum［J］. Dermatology, 2002,205（3）:221⁃223. doi: 10.1159/000065843. |
| ［51］ | Al Ghazal P, Dissemond J. Therapy of pyoderma gangrenosum in Germany: results of a survey among wound experts［J］. J Dtsch Dermatol Ges, 2015,13（4）:317⁃324. doi: 10.1111/ddg.12585. |
| ［52］ | Jain AG, Sharbatji M, Afzal A, et al. Pyoderma gangrenosum in the absence of any underlying predisposing condition: a diagnostic dilemma［J］. Cureus, 2019,11（3）:e4213. doi: 10. 7759/cureus.4213. |
| ［53］ | Marzano AV, Trevisan V, Lazzari R, et al. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum［J］. J Dermatolog Treat, 2010,21（3）:140⁃143. doi: 10.3109/09546630903268239. |
| ［54］ | Thomas KS, Ormerod AD, Craig FE, et al. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study［J］. J Am Acad Dermatol, 2016,75（5）:940⁃949. doi: 10.1016/j.jaad.2016.06.016. |
| ［55］ | Patel F, Fitzmaurice S, Duong C, et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review［J］. Acta Derm Venereol, 2015,95（5）:525⁃531. doi: 10. 2340/00015555⁃2008. |
| ［56］ | Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment［J］. Expert Rev Clin Immunol, 2018,14（3）:225⁃233. doi: 10.1080/1744666X.2018.1438269. |
| ［57］ | Alavi A, French LE, Davis MD, et al. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment［J］. Am J Clin Dermatol, 2017,18（3）:355⁃372. doi: 10.1007/s40257⁃017⁃0251⁃7. |
| ［58］ | Partridge A, Bai JW, Rosen CF, et al. Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials［J］. Br J Dermatol, 2018,179（2）:290⁃295. doi: 10.1111/bjd.16485. |
| ［59］ | Kolios A, Gübeli A, Meier B, et al. Clinical disease patterns in a regional swiss cohort of 34 pyoderma gangrenosum patients［J］. Dermatology, 2017,233（4）:268⁃276. doi: 10.1159/000481432. |
| ［60］ | Mekkes JR. Treatment of pyoderma gangrenosum［J］. BMJ, 2015,350:h3175. doi: 10.1136/bmj.h3175. |
| ［61］ | 臧箫, 李洪达, 刘永霞, 等. 阿达木单抗治疗坏疽性脓皮病一例并文献复习［J］. 中国麻风皮肤病杂志, 2023,39（1）:15⁃17. doi: 10.12144/zgmfskin202301015. |
| ［62］ | Wu Z, Xu QY, Yao ZR. Recalcitrant pediatric pyoderma gangrenosum controlled with adalimumab[J]. Int J Dermatol Venerol, 2022. doi: 10.1097/JD9.0000000000000258. |
| ［63］ | McPhie ML, Kirchhof MG. Pyoderma gangrenosum treated with secukinumab: a case report［J］. SAGE Open Med Case Rep, 2020,8:2050313X20940430. doi: 10.1177/2050313X20940430. |
| ［64］ | Tee MW, Avarbock AB, Ungar J, et al. Rapid resolution of pyoderma gangrenosum with brodalumab therapy［J］. JAAD Case Rep, 2020,6（11）:1167⁃1169. doi: 10.1016/j.jdcr.2020. 08.033. |
| ［65］ | Fahmy M, Ramamoorthy S, Hata T, et al. Ustekinumab for peristomal pyoderma gangrenosum［J］. Am J Gastroenterol, 2012,107（5）:794⁃795. doi: 10.1038/ajg.2012.42. |
| ［66］ | Burgdorf B, Schlott S, Ivanov IH, et al. Successful treatment of a refractory pyoderma gangrenosum with risankizumab［J］. Int Wound J, 2020,17（4）:1086⁃1088. doi: 10.1111/iwj.13359. |
| ［67］ | Baier C, Barak O. Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum［J］. JAAD Case Rep, 2021,8:43⁃46. doi: 10.1016/j.jdcr.2020.12.005. |
| ［68］ | Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA （pyogenic arthritis, pyoderma gangrenosum and acne） syndrome with the recombinant human interleukin⁃1 receptor antagonist anakinra［J］. Br J Dermatol, 2009,161（5）:1199⁃1201. doi: 10.1111/j.1365⁃2133.2009.09404.x. |
| ［69］ | Geusau A, Mothes⁃Luksch N, Nahavandi H, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA⁃like syndrome responding to canakinumab treatment［J］. JAMA Dermatol, 2013,149（2）:209⁃215. doi: 10.1001/2013.jamadermatol.717. |
| ［70］ | Choong DJ, Ng JL, Vinciullo C. Pyoderma gangrenosum associated with Takayasu's arteritis in a young Caucasian woman and response to biologic therapy with tocilizumab［J］. JAAD Case Rep, 2021,9:4⁃6. doi: 10.1016/j.jdcr.2020.12.034. |
| ［71］ | Ma L, Chen X, Guo Q, et al. Rapid response to spesolimab in a patient with severe refractory pyoderma gangrenosum［J］. Clin Exp Dermatol, 2023,49（1）:82⁃84. doi: 10.1093/ced/llad317. |
| ［72］ | Guénin SH, Khattri S, Lebwohl MG. Spesolimab use in treatment of pyoderma gangrenosum［J］. JAAD Case Rep, 2023,34:18⁃22. doi: 10.1016/j.jdcr.2023.01.022. |
| ［73］ | Ehrl DC, Heidekrueger PI, Broer PN. Pyoderma gangrenosum after breast surgery: a systematic review［J］. J Plast Reconstr Aesthet Surg, 2018,71（7）:1023⁃1032. doi: 10.1016/j.bjps.2018. 03.013. |
| ［74］ | Ebrad S, Severyns M, Benzakour A, et al. Pyoderma gangrenosum after orthopaedic or traumatologic surgery: a systematic revue of the literature［J］. Int Orthop, 2018,42（2）:239⁃245. doi: 10.1007/s00264⁃017⁃3672⁃2. |
| ［75］ | Orfaly VE, Kovalenko I, Tolkachjov SN, et al. Tofacitinib for the treatment of refractory pyoderma gangrenosum［J］. Clin Exp Dermatol, 2021,46（6）:1082⁃1085. doi: 10.1111/ced.14683. |
| ［76］ | Scheinberg M, Machado LA, M Castro LG, et al. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor［J］. J Transl Autoimmun, 2021,4:100099. doi: 10.1016/j.jtauto.2021.100099. |
| ［77］ | Laird ME, Tong LX, Lo Sicco KI, et al. Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum［J］. JAAD Case Rep, 2017,3（3）:228⁃229. doi: 10.1016/j.jdcr. 2017.02.019. |
| ［78］ | Sood AK, McShane DB, Googe PB, et al. Successful treatment of PAPA syndrome with dual adalimumab and tacrolimus therapy［J］. J Clin Immunol, 2019,39（8）:832⁃835. doi: 10.1007/s10875⁃019⁃00685⁃6. |
| ［79］ | Foley CC, Laing M. Paraneoplastic pyoderma gangrenosum successfully treated with minocycline and low⁃dose steroids［J］. J Eur Acad Dermatol Venereol, 2015,29（1）:184⁃185. doi: 10. 1111/jdv.12384. |
| ［80］ | Yamanaka K, Murota H, Goto H, et al. Pyoderma gangrenosum and annular erythema associated with Sjögren's syndrome controlled with minocycline［J］. J Dermatol, 2015,42（8）:834⁃836. doi: 10.1111/1346⁃8138.12897. |
| ［81］ | Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen［J］. Cutis, 1996,57（5）:315⁃319. |
| ［82］ | 袁玉婷, 陈瑜, 李莹, 等. 坏疽性脓皮病中西医治疗概述［J］. 中华中医药杂志, 2017,32（8）:3614⁃3617. |
| ［83］ | 孟建霞, 徐旭英, 王萍, 等. 培本固元法治愈坏疽性脓皮病［J］. 中华中医药杂志, 2018,33（10）:4480⁃4482. |
| ［84］ | 杨曦, 史哲新. 骨髓增生异常综合征合并坏疽性脓皮病1例并文献复习［J］. 白血病•淋巴瘤, 2024,33（6）:365⁃368. doi: 10.3760/cma.j.cn115356⁃20220801⁃00222. |
| ［85］ | Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series［J］. Br J Dermatol, 2018,178（2）:363⁃368. doi: 10.1111/bjd.15850. |
| ［86］ | 张航, 董慧婷. 增殖型坏疽性脓皮病一例［J］. 中华皮肤科杂志, 2017,50（9）:657. doi: 10.3760/cma.j.issn.0412⁃4030.2017.09. 009. |
| ［87］ | Din RS, Tsiaras WG, Li DG, et al. Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review［J］. J Drugs Dermatol, 2018,17（10）:1058⁃1060. |
| ［88］ | Rampal P, Benzaken S, Schneider S, et al. Colchicine in pyoderma gangrenosum［J］. Lancet, 1998,351（9109）:1134⁃1135. doi: 10.1016/S0140⁃6736（05）79420⁃4. |
| ［89］ | Vacas AS, Torre AC, Bollea⁃Garlatti ML, et al. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients［J］. Int J Dermatol, 2017,56（4）:386⁃391. doi: 10.1111/ijd.13591. |
| [1] | 姜倩 胡彬 陈瑶 陈柳青. 儿童面部获得性色素沉着斑131例临床及影像学特征回顾分析[J]. 中华皮肤科杂志, 2025, 58(9): 843-847. |
| [2] | 戴叶芹 宋秀祖. 毛囊及毛囊细胞移植在白癜风治疗中的应用进展[J]. 中华皮肤科杂志, 2025, 58(9): 882-885. |
| [3] | 徐中奕 邢小雪 董雅琦 张成锋 项蕾红. 上海市某三甲医院黄褐斑患者254例临床特征及疗效的回顾性分析[J]. 中华皮肤科杂志, 2025, 58(9): 808-815. |
| [4] | 姜子琪 钟菊丹 陈廷巧 陈瑾. 黄褐斑发病机制及治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(9): 868-872. |
| [5] | 钟洁敏 李薇 张淑娟 杨艳 薛如君 李欣怡 柯娅楠 陈晓吟 陈荃. 纳米微针与超声波导入氨甲环酸治疗黄褐斑的疗效与安全性比较：一项随机对照研究[J]. 中华皮肤科杂志, 2025, 58(9): 829-833. |
| [6] | 朱婷婷, 李蔚然 潘召兵 刘昊 唐先发 朱才红 黄鹤群 段大威 张若晨 陈小建 汪洋 薛倩 张菊锐 杨丽婧 张学军, 黄贺, 张博, . 巴瑞替尼联合芦可替尼乳膏治疗6例进展期非节段型白癜风患者的疗效观察[J]. 中华皮肤科杂志, 2025, 58(9): 856-859. |
| [7] | 周妙妮 盛安琪 傅丽芳 金嵘 许文 尉晓冬 许爱娥. 茶多酚抗氧化凝胶联合窄谱中波紫外线治疗白癜风的疗效及安全性单中心随机对照试验[J]. 中华皮肤科杂志, 2025, 58(9): 834-838. |
| [8] | 罗帅寒天 龙海 陆前进. 2024年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2025, 58(8): 777-780. |
| [9] | 中国医师协会皮肤科医师分会痤疮学组 中国研究型医院学会皮肤科学专业委员会 中国中西医结合学会皮肤性病专业委员会痤疮学组. [开放获取] 寻常痤疮临床严重度分级及疗效评价中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 709-714. |
| [10] | 薛珂 陈佳 李斌. 系统性红斑狼疮靶向治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(8): 781-784. |
| [11] | 陆前进 曹淑梅 蒋娇. 红斑狼疮研究的现状与挑战[J]. 中华皮肤科杂志, 2025, 58(8): 715-728. |
| [12] | 柏琪 朱明芳 邬清婷 姬孝天 杨慧怡 马莉苹 周佳欣. 青藤碱对DNCB诱导的特应性皮炎样模型小鼠皮损改善的作用研究[J]. 中华皮肤科杂志, 2025, 58(8): 759-766. |
| [13] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. [开放获取] 局限性硬皮病诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 699-708. |
| [14] | 林尽染 梁晓进 刘庆梅 吴文育. 雄激素性秃发与代谢综合征的关联：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2025, 58(7): 591-594. |
| [15] | 吕书影 王英 林文君 杨顶权. 联合托法替布治疗21例匐行性斑秃回顾性分析[J]. 中华皮肤科杂志, 2025, 58(7): 630-635. |
|
||
